Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05165095

Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers

The purpose of the clinical investigation is to document the safety and the performances of the remote monitoring functions of the ALIZEA, BOREA and CELEA pacemakers, i.e. the RAAT, the RVAT and the remote alerts.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsklinikum Krems, Krems, Austria

Loading trial locations.

About this study

All patients will be included just after implantation and will then be followed during 48 months after inclusion.

At each on-site or remote follow-up visit (1 to 3 months, 6, 12, 24 and 48 months), performances of the remote monitoring functions and the cardiac pacing system itself will be measured, and safety will be monitored during the whole clinical investigation duration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient implanted according to the most recent guidelines from the ESC, for 20 days or less (de novo implantation, device upgrade to dual chamber or device replacement)
  • Patient implanted with an ALIZEA, BOREA or CELEA dual chamber pacemaker from MicroPort CRM
  • Patient implanted with any active or passive CE marked bipolar RA lead, and any active or passive CE marked bipolar RV lead
  • Patient's pacemaker with the remote monitoring functions (i.e. the RAAT, the RVAT and the remote alerts) accepted by the patient and planned to be activated
  • Patient reviewed, signed and dated the ICF

Exclusion criteria

  • Patient with an elevated RV pacing threshold (strictly above 2.0 V for a pulse width of 0.5 ms or below)
  • Patient with permanent AF
  • Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
  • Patient implanted despite a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient contraindicated for a single dose of 310 μg of dexamethasone sodium phosphate, patient implanted with a tricuspid replacement heart valve or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
  • Minor age patient (i.e. under 18 years of age)
  • Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
  • Patient unavailable for the follow-up visits scheduled
  • Non-menopausal women

Treatment and study plan

Pacemaker implantation

Device

De novo implantation, device upgrade to dual chamber or device replacement

Primary outcomes

  1. Right Atrial Autothreshold values at the inclusion and the M1-M3 visits

    Time frame: 1 to 3 months post-inclusion visit (M1-M3)

  2. In-clinic Right Ventricular pacing threshold values from Right Ventricular Autothreshold function at the inclusion and the M1-M3 visits

    Time frame: 1 to 3 months post-inclusion visit (M1-M3)

  3. Technical remote alerts documented at the M1-M3 visit

    Time frame: 1 to 3 months post-inclusion visit (M1-M3)

Secondary outcomes

  1. Right Atrial Autothreshold values up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

  2. In-clinic Right Ventricular pacing threshold values from Right Ventricular Autothreshold function up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

  3. Technical remote alerts documented up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

  4. Right Ventricular Autothreshold values up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

  5. Safety of ALIZEA, BOREA and CELEA pacemaker and of SMARTVIEW CONNECT remote monitoring systems up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

  6. Electrical performances (pacing thresholds, impedance & minimum sensed amplitude) of ALIZEA, BOREA and CELEA pacemaker systems up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

  7. Usability of ALIZEA, BOREA and CELEA pacemaker and of SMARTVIEW CONNECT remote monitoring systems up to the M48 visit

    Time frame: 48 months post-inclusion visit (M48)

Study contacts

Contact information is provided by the study sponsor or research team.

Antoine Guihard

CONTACT

[email protected]

+33 1 46 01 33 20

Sponsors and collaborators

Lead sponsor

MicroPort CRM

Industry

Registry information

Acronym: CALLIOPE

Important dates

Study start
2022
Primary completion
2023
Study completion
2027
First posted
Dec 21, 2021
Registry last updated
May 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.